Glovadalen (developmental code name UCB-0022) is a dopamine D1 receptor positive allosteric modulator which is under development for the treatment of Parkinson's disease.[1][2][3][4][5][6] It has been found to potentiate the capacity of dopamine to activate the D1 receptor by 10-fold in vitro with no actions on other dopamine receptors.[5][6] As of May 2024, glovadalen is in phase 2 clinical trials for this indication.[1][2][5] The drug is under development by UCB Biopharma.[1][4][5] It is described as an orally active, centrally penetrant small molecule.[1][5][6]
![]() | |
Clinical data | |
---|---|
Other names | UCB-0022; UCB0022 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
UNII | |
Chemical and physical data | |
Formula | C24H27Cl2N3O3 |
Molar mass | 476.40 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ a b c d "UCB 0022". AdisInsight. Springer Nature Switzerland AG. 28 May 2024. Retrieved 10 August 2024.
- ^ a b "Delving into the Latest Updates on Glovadalen with Synapse". Synapse. 8 August 2024. Retrieved 10 August 2024.
- ^ McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, et al. (2023). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update". Journal of Parkinson's Disease. 13 (4): 427–439. doi:10.3233/JPD-239901. PMC 10357160. PMID 37302040.
Our analysis of dopaminergic therapies shows a continued emphasis on DA agonists and levodopa reformulation. These include Cerevel's tavapadon, a D1/D5 receptor partial agonist and UCB0022, a positive allosteric modulator of the D1 receptor, as well as approaches to sub-cutaneously deliver levodopa/carbidopa such as Abbvie's ABBV-951 and Neuroderm's ND0612.
- ^ a b "Glovadalen". IUPHAR/BPS Guide to PHARMACOLOGY. Retrieved 10 August 2024.
- ^ a b c d e "UCB0022". ALZFORUM. 3 May 2024. Retrieved 10 August 2024.
- ^ a b c Vermeiren C, Ates A, Bouzom F, Delaunois A, Gillard M, Kenda B, et al. (7 September 2022). "Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)". Movement Disorders. 37 (Suppl 2 [2022 International Congress September 15-18, 2022. Madrid, Spain]). Retrieved 10 August 2024.